Nascent Biotech logo

Nascent Biotech(OTC) NBIO

Market Cap$34.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-67%
1 Month+100%
$0.00
+0.00%
+0.00Today
Nascent Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-14
Nascent Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-10-05
1 month+100%USD 0.002026-09-10
3 month-66.67%USD 0.002026-07-14
Year to date-66.67%USD 0.002025-12-31
1 year-66.67%USD 0.002025-10-14
3 year-99.86%USD 0.142023-10-13
5 year-99.75%USD 0.082021-10-15
Since inception-99.98%USD 1.012014-08-05

Nascent Biotech Financials at a Glance

Market Cap

$34.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.38

Net Income (TTM)

-$1.35M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.57 (Low)

Price

$0.00

Volume

38,073

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.13

Estimated Earnings Date

Jul 4, 2025

NBIO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nascent Biotech

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody-based treatments for various cancers. The company is primarily advancing Pritumumab, a therapeutic targeting aggressive brain malignancies and other epithelial cancers.

Products and Services
  • Pritumumab for treating glioblastoma and malignant astrocytoma
  • MultiPharm technology platform for cancer therapy and autoimmune disorders
  • Research and development in monoclonal antibody treatments
Growth Outlook
  • Potential market for Pritumumab in aggressive brain cancers is significant
  • Advancements in MultiPharm could diversify treatment applications
  • Increased focus on oncology presents growth opportunities
Financial Highlights
  • Recent quarterly net income of -$252,000 reflects ongoing R&D investments
  • Trailing twelve months show a cash position of $1,822
  • Operating expenses totaled $251,226 in the latest quarter
Nascent Biotech, Inc. is positioned in the biotechnology sector, focusing on innovative cancer treatments. The company's lead product, Pritumumab, is in development to address critical needs in oncology, particularly for aggressive brain tumors. The MultiPharm platform further enhances the company's potential by offering a range of applications beyond oncology, including diabetes and autoimmune disorders. Recent financial data indicates a commitment to research and development, with significant investments aimed at advancing product pipelines. The latest quarterly report shows a net income loss, which is typical for clinical-stage companies investing heavily in R&D. Despite the challenges, the potential market for Pritumumab and the innovative nature of the MultiPharm platform present promising growth opportunities for the company. Investors may find interest in the company's strategic focus on high-need therapeutic areas and its commitment to advancing novel treatments in the biopharmaceutical landscape.
AI Generated • Sep 26, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Sean Carrick

Website

www.nascentbiotech.com

Headquarters

North Palm Beach, FL 33408, US

NBIO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

268.93%

Return on Capital

N/A

Return on Assets

-378.18%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$34.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

172.84M

Volume

38.07K

Avg. Volume

22.63K

Financials (TTM)

Gross Profit

-$295.63K

Operating Income

-$1.51M

EBITDA

-$591.74K

Operating Cash Flow

-$1.35M

Capital Expenditure

-$2.00

Free Cash Flow

-$1.35M

Cash & ST Invst.

$1.82K

Total Debt

$59.00K

Nascent Biotech Performance Analysis

Nascent Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31USD 1,000,000N/A
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
Nascent Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-12-31N/A
Q42024-03-31N/A
Q12024-06-30-100.0%
Q22024-09-30N/A
Nascent Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31USD -0.00N/A
20232023-03-31USD -0.02436.4%
20242024-03-31USD -0.01-43.2%
Nascent Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-12-3178.6%
Q42024-03-31-150.0%
Q12024-06-3026.7%
Q22024-09-3031.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$34.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$17.30K

N/A

Employees

2

N/A

Net Income

-$252.00K

+69.6%

EBITDA

-$251.00K

+56.4%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$1.82K

-99.8%

Total Debt

$59.00K

-80.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$59.00K

-80.7%

Return on Assets

-3.78%

N/A

Return on Invested Capital

8.69%

N/A

Free Cash Flow

-$324.73K

-99.6%

Operating Cash Flow

-$324.73K

-99.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RLBDReal Brands, Inc.
$0.00+0.00%
PZOOPazoo, Inc.
$0.00+0.00%
VIVXFAvivagen Inc.
$0.00+0.00%
RGRXRegeneRx Biopharmaceuticals, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About NBIO

What is the current price of Nascent Biotech?

Nascent Biotech is trading at $0.00 per share.

What is the 52-week range for Nascent Biotech?

Over the past 52 weeks, Nascent Biotech has traded between $0.00 and $0.13.

How much debt does Nascent Biotech have?

As of the most recent reporting period, Nascent Biotech reported total debt of $122.50K.

How much cash does Nascent Biotech have on hand?

Nascent Biotech reported $372.12K in cash and cash equivalents in its most recent financial results.

What is Nascent Biotech’s dividend yield?

Nascent Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services